PMID- 34050375
OWN - NLM
STAT- MEDLINE
DCOM- 20210928
LR  - 20210928
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
VI  - 42
IP  - 7
DP  - 2021 Oct
TI  - Aspirin Use and Transcatheter Pulmonary Valve Replacement, the Need for 
      Consistency.
PG  - 1640-1646
LID - 10.1007/s00246-021-02652-8 [doi]
AB  - Transcatheter pulmonary valve replacement (TPVR) is a staple in the pediatric 
      cardiac catheterization lab. Despite the ubiquitous use of this procedure, 
      guidelines for antithrombosis post pulmonary valve replacement are non-existent. 
      A survey was sent out via email to the members of the Congenital Cardiovascular 
      Interventional Study Consortium (CCISC) and the Pediatric and Adult 
      Interventional Cardiac Symposium (PICS-AICS). Responses were received from 109 
      cardiologists who perform this procedure. Following TPVR 76.5% of respondents use 
      only Aspirin, while the remainder prescribe a second antithrombotic agent at 
      discharge. The majority (78%) of respondents do not educate patients about 
      avoiding enteric formulations of aspirin, and another 86% do not educate patients 
      about the need to avoid proton pump inhibitors (PPI). In addition, 67% do not 
      advise against concomitant use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 
      Lastly, the survey showed a wide discrepancy in prescribed dose with 56% choosing 
      to always prescribe 70-100 mg regardless of weight, 28% choosing to do 
      weight-based dosing, and 7.5% choosing 325 mg regardless of weight. In a survey 
      sent out to pediatric cardiac interventionalists worldwide, a significant 
      discrepancy was noted in antithrombotic regimens used following TPVR. We 
      hypothesize that these discrepancies may contribute to early valve failure and 
      suggest the need for further study and the development of unified antithrombosis 
      guidelines following TPVR.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Shibbani, Kamel
AU  - Shibbani K
AD  - Division of Cardiology, Department of Pediatrics, University of Iowa Stead Family 
      Children's Hospital, Iowa City, IA, USA.
FAU - Garg, Ruchira
AU  - Garg R
AD  - Department of Pediatrics and Cardiology, Smidt Heart Institute, Cedars-Sinai 
      Medical Center, Los Angeles, CA, USA.
FAU - Zahn, Evan M
AU  - Zahn EM
AD  - Department of Pediatrics and Cardiology, Smidt Heart Institute, Cedars-Sinai 
      Medical Center, Los Angeles, CA, USA.
FAU - Mclennan, Daniel
AU  - Mclennan D
AUID- ORCID: 0000-0002-2545-1241
AD  - Division of Cardiology, Department of Pediatrics, Medical College of Wisconsin, 
      Milwaukee, WI, USA. dMcLennan@chw.org.
LA  - eng
PT  - Journal Article
DEP - 20210529
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aspirin
MH  - Cardiac Catheterization
MH  - Child
MH  - *Heart Valve Prosthesis
MH  - *Heart Valve Prosthesis Implantation
MH  - Humans
MH  - *Pulmonary Valve/surgery
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antithrombotic therapy
OT  - Aspirin
OT  - Guidelines
OT  - Thrombus
OT  - Transcatheter pulmonary valve replacement
OT  - Valve failure
EDAT- 2021/05/30 06:00
MHDA- 2021/09/29 06:00
CRDT- 2021/05/29 06:16
PHST- 2021/04/10 00:00 [received]
PHST- 2021/05/24 00:00 [accepted]
PHST- 2021/05/30 06:00 [pubmed]
PHST- 2021/09/29 06:00 [medline]
PHST- 2021/05/29 06:16 [entrez]
AID - 10.1007/s00246-021-02652-8 [pii]
AID - 10.1007/s00246-021-02652-8 [doi]
PST - ppublish
SO  - Pediatr Cardiol. 2021 Oct;42(7):1640-1646. doi: 10.1007/s00246-021-02652-8. Epub 
      2021 May 29.